Tissue-resident memory CD8 T cells (T RM ) provide preemptive immunity against infections that begin in peripheral tissues by guarding the site of initial pathogen exposure. Their role in immunity to respiratory virus infection is particularly important because severe damage to the alveoli can be avoided when local populations of T RM cells reduce viral burdens and dampen the responses of effector CD8 T cells in the lungs. Although a connection between rapid immune activation and early viral control is well established, the signals that keep T RM cells poised for action in the local tissues remain poorly defined. Recent studies have shown that environmental cues influence the fate decisions of activated CTLs during memory formation. Manipulation of these signaling pathways could provide new ways to capitalize on protection from T RM cells in mucosal tissues, while reducing collateral damage and pathology during vaccination.
Introduction
The lungs are comprised of 2 functionally distinct compartments with very different structural organization: one is the highly vascularized parenchymal tissue that is required for respiration and can be easily damaged during a robust immune response, and the other compartment includes the lumen and walls of the conducting airways, where the stratified epithelium is relatively resistant to immune damage. The organization of the tissues places constraints on the immune response because distinct populations of specialized memory CD8 T cells are required for local immune surveillance. Vascular tissues are perfused by memory CD8 T cells, which use the bloodstream to circulate around the body [1] . Additional populations of noncirculating T RM cells colonize the airways and reduce the quantities of infectious virus that reach the alveoli during secondary challenge [2, 3] . This mechanism of protection is an underused resource for vaccine development, largely because reliable methods for establishing local populations of memory CD8 T cells in the mucosal tissues are not currently available. Efforts to develop safe vaccines for pulmonary immunization have been hampered by a limited understanding of the signaling pathways that influence the fate decisions of activated CTLs during memory formation. Some recent progress in the field indicates that new methods of immunization could soon be on the horizon.
MECHANISMS OF PROTECTION BY PULMONARY T RM CELLS
Influenza viruses are genetically labile pathogens that constantly alter their surface proteins to evade the humoral immune response. CTLs overcome this problem by targeting conserved epitopes from internal viral proteins to provide cross-protection between serologically distinct strains [4] [5] [6] . Evidence that T RM cells make an important contribution to immunity became known after sequential infections with different strains of IAV revealed a weak correlation between the numbers of antiviral memory CD8 T cells in the circulation of mice that had recovered from a prior infection with IAV and the severity of disease during reinfection with another strain [7] . Robust cells that mediate immunity developed only when viral antigens were present in the respiratory tract during priming [8, 9] and declined as an unusual subset of activated CTLs disappeared from the airways [10] [11] [12] . These lung-resident CTLs exhibited characteristics of T RM cells in other barrier tissues and vital organs [3, 13, 14] , including stable CD69 expression [10] [11] [12] . Collectively, T RM cells are the largest subset of memory CD8 T cells in the body and can be found in most human tissues, including the lungs [15, 16] .
The mechanisms by which T RM cells enhance immunity may vary according to the site of infection. Early viral control in the female reproductive tract has been linked to rapid recruitment of immune cells to the site of inoculation [17] by a mechanism that can be mimicked using local delivery of inflammatory mediators [18] . Others found that T cellderived IFN-g enhanced immunity in the lungs by a similar mechanism after transfer [19] . Natural immunity to a respiratory infection is more complex because the lungs contain heterogeneous populations of memory CD8 T cells after pulmonary immunization, including some T CM cells, which move through the vasculature and undergo robust proliferation in the local lymph nodes after secondary challenge [20] . Images of the lungs taken during reinfection showed that very few migrating CTLs arrived in the airways before the viral burdens declined. The immunity was not compromised when an agonist of the sphingosine S1P receptor was used to sequester circulating CTLs in the lymph nodes during reinfection, indicating that lung-resident CTLs control viral replication [2, 21] .
Some pulmonary T RM cells can be collected from the lumen of the airways by BAL [12, 22] . These CTLs exhibit weak lytic activity in vitro [23] , which is caused by low CD11a expression after exposure to proteases in the lung surfactant (24, 25). It is not clear that the protease activity compromises immunity because many cells that enter the lumen of the airways are expelled from the lungs by the mucociliary escalator (26). Other T RM cells remain embedded in the walls of the airways [2] and maintain CD11a expression, which supports robust lytic activity in vitro (27). The predominant populations of pulmonary T RM cells also express aEb7 integrin (CD103), which resists protease digestion and can replace CD11a during cytolysis of infected epithelial cells [28] [29] [30] [31] . Together, these data indicate that pulmonary T RM cells are equipped to have an active role in viral clearance, rather than simply sending a distress signal to cells in other tissues. CTLs with markers of T RM cells had immediate lytic potential after recovery from human lungs [32] .
CHALLENGES FOR VACCINE DEVELOPMENT
Pulmonary infection is the most effective method for inducing robust cell-mediated immunity in the lungs but raises important safety concerns when applied as a vaccine strategy, thus creating an impetus for the use of alternative approaches. Immunization in distal tissues can also have unexpected consequences, as shown by experiments with mice that were primed with IAV by peritoneal injection to induce the formation of circulating memory CD8 T cells without accompanying T RM cells [2] . The mice were poorly protected against reinfection with another strain, even though large populations of antiviral memory CD8 T cells were found in the circulation [2, 7] . Ominously, the lungs were overwhelmed by massive numbers of reactivated CTLs, which proliferated in the lymph nodes before entering the respiratory tract a few days later (Fig.  1A) . By comparison, relatively few migrating CTLs entered the lungs of intranasally primed mice (Fig. 1B) , which had many T RM cells in the airways [2] . These observations are not consistent with a proinflammatory role for T RM 
KLRG1
+ CTLs that develop in response to vaccine delivery have little long-term value and could damage the lungs. Discovery of new therapeutic approaches that inhibit formation of T EFF cells during memory development could be a major advance for the treatment of pulmonary disease. Recent studies indicate that some progress has been made in this area.
Simplified experimental systems show that a brief period of antigen stimulation is sufficient for naïve CD8 T cells to embark on a self-perpetuating developmental program, which culminates in the formation of memory CD8 T cells [54] . The fate decisions of activated CTLs are controlled by a complex transcriptional network involving cooperative expression of T-bet and Zeb2 during a robust T EFF response [65] , whereas high eomesodermin expression favors memory formation [66, 67] . Evidence indicates that terminally differentiated T EFF cells are a product of asymmetric cell division, which can be triggered by robust stimulation through the antigen receptor [68, 69] . Individual precursors produce daughter cells with different capacities for long-term survival after uneven inheritance of critical regulatory factors, such as T-bet, mTORC1, and c-MYC [70, 71] . Robust signaling via the antigen receptor cannot entirely account for the dichotomy in the CTL response because T EFF cells do not up-regulate KLRG1 in vitro [72] . In vivo T EFF generation is driven by proinflammatory molecules that are released during infection [58, 73] . Defining the cytokine milieu that supports optimal memory formation is an important priority for vaccine development. Eventually it may be possible to block the paracrine signals that drive the T EFF response during vaccination (Fig. 3) , whereas preserving heterogeneity within the memory compartment is essential for T RM development and immunity.
This may be a complex task because activated CTLs receive costimulatory signals from a diverse array of proinflammatory cytokines during infection [74, 75] [72] . Although the ligand for the missing pathway remains elusive, some insightful clues about its influence on the CTL response can be found in the literature. Several studies have shown that regulation by TGF-b reduces the numbers of pathogenspecific CTLs that express KLRG1 during infection and autoimmunity, thus reducing pathology in mucosal tissues [61, [82] [83] [84] [85] . In other experiments, circulating memory CD8 T cells converted to a KLRG1 + phenotype upon temporal ablation of the TGF-b receptor, without exposure to cognate antigen [86] . Revealingly, the numbers of memory CD8 T cells that expressed KLRG1 after ablation of the TGF-b receptor were reduced when the mice were pretreated with antibiotics [86] , suggesting that the ligand for the unknown signaling pathway is expressed during infection or during exposure to microbial metabolites.
MOLECULAR CONTROL OF T RM DEVELOPMENT AND TISSUE LOCALIZATION
Eliciting protective CTL populations in the lungs by vaccination is a challenging endeavor because antigens must reach the lungs during T RM formation [19, 43, 46, 87] . Peptide antigens have a controversial role in tissue localization and may be dispensable for formation and/or maintenance of T RM cells at some sites [88, 89] . Tonic signaling through the TcR is required for CTLs to maintain canonical markers of T RM cells (CD69 and CD103) in tissues that lack an epithelial layer, such as the secondary lymphoid organs and brain [43, 90] . At other sites, CD69 expression may be maintained independent of the antigen receptor, including mucosal tissues, such as lungs [88, 89] . The CTLs that express CD69 do not enter the circulation when the receptor for S1P is modulated from the cell surface [91] [92] [93] . A related mechanism is required for T RM cells to settle in peripheral tissues, such as the lungs, where cytokines promote the formation of T RM cells and suppress expression of Kruppellike factor 2 and the S1P1 receptor [94] .
Most pulmonary T RM cells also express aeb7 integrin (CD103), which mediates interactions with epithelial cells that express E-cadherin and supports retention at the mucosal surface [31, 95] . Naive CD8 T cells constitutively express CD103, which may facilitate interactions with specialized DCs that express E-cadherin [96] . Expression disappears from the surface of activated CTLs soon after TCR stimulation and returns when memory CD8 T cells enter tissues containing TGF-b [46, 64] . The concentrations of TGF-b reach high levels during infection with mildly pathogenic strains of IAV and other pathogens that encode enzymes, which cleave the latent cytokine and release the active peptide that is responsible for receptor binding [97, 98] . Fewer T RM cells were found in the lungs of IAV-infected mice after targeted deletion of CD103 or TGF-b receptor II from T cells [46, 61] , indicating that interactions with E-cadherin promote retention of CD103 + T RM cells at the mucosal surface. Studies suggest that CD103 has a similar role in the gastrointestinal tract [99] and in positioning of tumor-infiltrating lymphocytes within the tumor microenvironment [100, 101] .
Expression of the Itgae gene (CD103) is controlled by integrated signals from the antigen receptor, and TGF-b and CD4 help [61, 63, 67, 102] . The TGF-b receptor employs multiple signaling pathways for immune regulation [103] , including a cascade Smads that are involved in regulation of the Itgae gene [102, 104, 105] . Smad4 is a central adaptor protein for multiple overlapping pathways and chaperones complexes of receptor-activated Smads into the nucleus during signal transduction [106] . A recent study showed that CTLs, which lack either the TGF-b receptor or Smad4, adopt reciprocal phenotypes during IAV infection [61] . Although the TGF-b receptor-deficient CTLs did not express CD103, targeted deletion of Smad4 was sufficient for widespread CD103 expression on antiviral CTLs in peripheral and lymphoid tissues [61] . Conversely, very few Smad4-deficient CTLs expressed KLRG1 or CD62L, which were highly expressed in the absence of the TGF-b receptor. Although some Smad4-deficient CTLs survived the contraction of the T EFF response, very few cells were found in the resting lymph nodes without CD62L expression [61] . Similar data from other models indicate that Smad4 deletion has a global effect on CD8 T cell differentiation [107, 108] . Surprisingly, the phenotype of the Smad4-deficient CTLs was not altered in the absence TGF-b receptor expression [108] [Y. Hu and L. Cauley, personal communication, December 10, 2015], indicating that an alternative signaling pathway is involved in regulation of the Itgae gene. Because Smad4 has a critical role in terminal differentiation of KLRG1 + CTLs, this pathway may provide new avenues for therapeutic intervention by blocking a robust T EFF response in the lungs during vaccination.
CONCLUDING REMARKS
Understanding the signaling pathways that modify the fate decisions of activated T cells is necessary for understanding immune responses to viral pathogens and may provide the key to optimal vaccine design. T EFF generation via external signaling is appealing to vaccinologists aiming to induce memory formation without the pathogenic CTLs that combat infection. Whether this concept will hold true for T RM cells in mucosal tissues remains to be determined, but an ability to manipulate the signaling pathways that drive memory formation would constitute an important step toward rational design of vaccines for pulmonary infections. 
